The Praluent Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The Praluent market has been experiencing a historical compound annual growth rate (HCAGR) of XX. It's anticipated to increase from a market size of $XX billion in 2024 to $XX billion in 2025, with a compound annual growth rate (CAGR) of XX%.
The Praluent market is forecasted to increase to a value of $XX billion in 2029, with an anticipated compound annual growth rate (CAGR) of XX%.
Download Your Free Sample of the 2025 Praluent Market Report and Uncover Key Trends Now!The key drivers in the praluent market are:
• Increasing prevalence of cardiovascular diseases leading to higher demand for cholesterol-lowering treatments
• Growing awareness and management of hyperlipidemia
• Expanding use of PCSK9 inhibitors in treatment protocols
• Increased adoption of personalized medicine and rising healthcare investments
The praluent market covered in this report is segmented –
1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)
2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies
3) By End-User: Ambulatory Care, Home Care
The key trends in the praluent market are:
• Development of higher-dose formulations is an emerging trend in the market.
• Advancements in drug delivery devices are increasingly influencing the market structure.
• The praluent global market is adopting digital health technologies for remote monitoring.
• The adoption of personalized medicine is a significant upcoming trend shaping the Praluent Global market.
Major players in the praluent market are:
• Sanofi S.A.
• Regeneron Pharmaceuticals Inc.
North America was the largest region in the praluent market in 2024